BioXcel Therapeutics Inc
(NAS:BTAI)
$
0.414
0.022 (5.61%)
Market Cap: 20.55 Mil
Enterprise Value: 85.13 Mil
PE Ratio: 0
PB Ratio: 0
GF Score: 19/100 BioXcel Therapeutics Inc at Bank of America NAPA Healthcare Conference Transcript
Jun 14, 2021 / 03:30PM GMT
Release Date Price:
$38.36
(+1.32%)
Geoffrey Christopher Meacham
BofA Securities, Research Division - Research Analyst
(technical difficulty) and wish that next year, it will be in person. But it is what it is. We're thrilled to have in the very first session for today, BioXcel Therapeutics. And sitting with us here is CEO, Vimal Mehta; and we also have Will Kane, who is Head of Commercial. Guys, welcome.
Vimal D. Mehta
BioXcel Therapeutics, Inc. - Founder, CEO, President, & Director
Thank you, Geoff.
William P. Kane
BioXcel Therapeutics, Inc. - Executive VP & Chief Commercial Officer
Welcome, Geoff.
Geoffrey Christopher Meacham;Vimal D. Mehta
BofA Securities, Research Division - Research Analyst;BioXcel Therapeutics, Inc. - Founder, CEO, President,
All right. So we'll kick it off with just anything that you guys wanted to start off with prepared remark wise, we have a lot of questions here. We have some questions from investors as well. So, Vimal, over to you.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot